

A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term, Safety and Tolerability of RT001 in Subjects with Friedreich's Ataxia

University of California-Los Angeles (UCLA) is actively recruiting children and adults with Friedreich's ataxia (FA) for a Phase 2/3 study assessing efficacy, long-term safety and tolerability of RT001.

We are currently recruiting patients between 12-50 years of age who have a genetic diagnosis of FA.

To qualify for the study, you must:

- Have a genetic confirmation of your FA
- Have been diagnosed with FA at age 25 years or younger
- Be able to ride a recumbent bike
- Be able to walk 25 feet or more within a minute, with or without the use of an assistive device
- Engage in phone calls with a dietician and study coordinator

In addition,

- Do **not** have a medical condition that may interfere with drug administration
- Have **not** previously participated in a Retrope study in FA
- Do **not** have a history of cancer or malignancy other than basal cell carcinoma
- **Cannot** be pregnant, breastfeeding, or planning a pregnancy
- **Cannot** take any fish oil or oil-based supplements for the duration of the study

Participants will be reimbursed up to a certain amount per visit

To learn more about the study, contact one of the study coordinators below:

Hayward, Dillan Email: DHayward@mednet.ucla.edu Tel: (310) 206-8153 [Ataxia]

Fisher, Aaron Email: ADFisher@mednet.ucla.edu Tel: (310) 206-8153 [Ataxia]